

PharmLabs San Diego Certificate of Analysis



Sample Red Devil Cartridge 2000mg D8/HHC/ THCP Blue Dream

Delta9 THC UI | THCa ND | Total THC (THCa * 0.877 + THC) UI | Delta8 THC 38.47%

Sample ID SD230630-012 (80726) Matrix Concentrate
 Tested for Red Devil
 Received Jun 29, 2023 Reported Jul 03, 2023
 Analyses executed CANX Unit Mass (g) 2.0

Laboratory note: The estimated concentration of the unknown peak in the sample is 9.67% | Currently PharmLabs laboratory can not confirm an unidentified peak in your chromatogram due to interference (only with highly concentrated D8 products) from which we believe to be either (+)d8-THC or d9-THC. At this time there are no reference standards available for (+)d8-THC. (+)d8-THC is a different compound from the main (-)d8-THC cannabinoid and, therefore, these two compounds may have different efficacies. Using the most advanced instruments and techniques available, the separation of (+)d8-THC and d9-THC is problematic for the scientific community as a whole. PharmLabs believes the unidentified peak to be a combination of (+)d8-THC and d9-THC with the majority, if not all, of the concentration being (+)d8-THC. Total (+/-) D8 Concentration is estimated to be: 38.47%

CANx - Cannabinoids

Analyzed Jul 03, 2023 | Instrument HPLC-VWD | Method SOP-001
 The expanded Uncertainty of the Cannabinoids analysis is approximately ±7.81% at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Unit
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THCV)	0.013	0.041	ND	ND	ND
Cannabinol (CBDO)	0.006	0.02	ND	ND	ND
Abnormal Cannabinol (a-CBDO)	0.013	0.038	ND	ND	ND
(+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC)	0.015	0.045	ND	ND	ND
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC)	0.015	0.045	ND	ND	ND
Cannabinolic Acid (CBDA)	0.033	0.16	ND	ND	ND
Cannabigerol Acid (CBGA)	0.033	0.16	ND	ND	ND
Cannabigerol (CBG)	0.048	0.16	ND	ND	ND
Cannabinol (CBD)	0.069	0.229	ND	ND	ND
1(S)-Tetrahydrocannabinol (1(S)-H4-CBD)	0.008	0.026	ND	ND	ND
1(R)-Tetrahydrocannabinol (1(R)-H4-CBD)	0.016	0.049	ND	ND	ND
Tetrahydrocannabinol (THCV)	0.049	0.162	ND	ND	ND
Δ8-tetrahydrocannabinol (Δ8-THCV)	0.021	0.064	ND	ND	ND
Cannabidiol (CBDH)	0.014	0.042	ND	ND	ND
Tetrahydrocannabinol (Δ9-THCB)	0.01	0.029	ND	ND	ND
Cannabinol (CBN)	0.047	0.16	1.03	10.29	20.58
Cannabidiol (CBDP)	0.016	0.049	ND	ND	ND
exo-THC (exo-THC)	0.016	0.8	ND	ND	ND
Tetrahydrocannabinol (Δ9-THC)	0.092	0.307	UI	UI	UI
Δ8-tetrahydrocannabinol (Δ8-THC)	0.044	0.16	38.47	384.70	769.40
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.015	0.8	ND	ND	ND
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.8	7.88	78.80	157.60
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.007	0.8	ND	ND	ND
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.8	19.43	194.30	388.60
Tetrahydrocannabinolic Acid (THCA)	0.117	0.389	ND	ND	ND
Δ9-Tetrahydrocannabinol (Δ9-THCH)	0.02	0.061	ND	ND	ND
Cannabinol Acetate (CBNO)	0.009	0.027	ND	ND	ND
Δ9-Tetrahydrocannabinol (Δ9-THCP)	0.017	0.8	0.69	6.88	13.77
Δ8-Tetrahydrocannabinol (Δ8-THCP)	0.041	0.8	ND	ND	ND
Cannabicitran (CBT)	0.005	0.16	ND	ND	ND
Δ8-THC-O-acetate (Δ8-THCO)	0.076	0.8	ND	ND	ND
9(S)-HHC (s-HHCP)	0.013	0.041	ND	ND	ND
Δ9-THC-O-acetate (Δ9-THCO)	0.066	0.8	ND	ND	ND
9(R)-HHC (r-HHCP)	0.015	0.045	ND	ND	ND
9(S)-HHC-O-acetate (s-HHCO)	0.037	0.112	ND	ND	ND
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.021	0.062	ND	ND	ND
Δ9-THC methyl ether (Δ9-MeO-THC)	0.029	0.088	ND	ND	ND
Total THC (THCa * 0.877 + Δ9THC)			UI	UI	UI
Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC)			38.47	384.70	769.40
Total CBD (CBDA * 0.877 + CBD)			ND	ND	ND
Total CBG (CBGA * 0.877 + CBG)			ND	ND	ND
Total HHC (9r-HHC + 9s-HHC)			27.31	273.10	546.20
Total Cannabinoids Analyzed			67.50	674.97	1349.95



UI Unidentified
 ND Not Detected
 N/A Not Applicable
 NT Not Reported
 LOD Limit of Detection
 LOQ Limit of Quantification
 <LOQ Detected
 >ULOL Above upper limit of linearity
 CFU/g Colony Forming Units per 1 gram
 TNTC Too Numerous to Count



DEA license: RP0611043
 ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr

Brandon Starr, Quality Assurance Manager
 Mon, 03 Jul 2023 13:02:14 -0700

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368



PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2019 Form 991. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.